Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs

被引：0
|
作者：
Kaumaya, P. T. P. [1 ]
Overholser, J. [2 ]
Guo, L. [2 ]
Yang, Y. [3 ]
Penichet, M. [4 ]
Sayanjali, B. [2 ]
Ede, N. [5 ]
Chong, L. [6 ]
Bekaii-Saab, T. [7 ]
机构：
[1] Ohio State Univ, Med Ctr, James Comprehens Canc Ctr, OB Gyn, Columbus, OH 43210 USA
[2] Ohio State Univ, Med Ctr, OB Gyn, Columbus, OH 43210 USA
[3] Ohio State Univ, Med Ctr, Neurol, Columbus, OH 43210 USA
[4] Univ Calif Los Angeles, Med, Los Angeles, CA USA
[5] Imugene, Technol, Carlton, Vic, Australia
[6] Imugene, Sydney, NSW, Australia
[7] Mayo Clin, Med Oncol, Ctr Canc, Phoenix, AZ USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1218P
引用
收藏
页数：2
相关论文
共 5 条
  • [1] Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumor growth in a syngeneic Balb/c model challenged with CT26/HER-2 carcinoma cell line
    Bekaii-Saab, Tanios
    Overholser, Jay
    Yang, Yuhong
    Penichet, Manuel
    Kaumaya, Pravin
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Antitumor activity of a novel allogeneic colorectal cancer vaccine in C57BL/6 mice bearing MC38 anti-PD1 resistant colon carcinoma syngeneic model with TME
    Gongora, Celine
    Kress, Elsa
    Vermot-Desroches, Claudine
    Chalus, Lionel
    Forget, Jeremy
    Pinteur, Benoit
    Bravetti, Paul
    Dumontet, Charles
    Italiano, Antoine
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
    Guo, Linlin
    Overholser, Jay
    Good, Anthony J.
    Ede, Nicholas J.
    Kaumaya, Pravin T. P.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
    Kaumaya, Pravin T. P.
    Guo, Linlin
    Overholser, Jay
    Penichet, Manuel L.
    Bekaii-Saab, Tanios
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [5] A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)
    Guo, Linlin
    Overholser, Jay
    Darby, Heather
    Ede, Nicholas J.
    Kaumaya, Pravin T. P.
    ONCOIMMUNOLOGY, 2022, 11 (01):
1